MELATONIN Information for Primary Care
|
|
- Paula Young
- 5 years ago
- Views:
Transcription
1 North of Tyne Area Prescribing Committee Shared Care Group MELATONIN Information for Primary Care Background Melatonin is a hormone secreted by the pineal gland. It is normally secreted at night and its main function is the regulation of circadian rhythm and sleep, playing an important role in setting the correct timing of sleep-wake cycles. The administration of exogenous melatonin has a rapid, transient, mild sleep inducing effect and it lowers alertness, body temperature and performance for about 3 to 4 hours after the administration of low doses (of immediate release formulations). Melatonin has been used in the UK as an unlicensed medicine for several years on the advice of hospital specialists, for limited use in the treatment of a variety of sleep disorders.a licensed modified release product is also available. The North of Tyne Area Prescribing Committee has approved the use of melatonin for the following indications: Approved Indications Melatonin can be used to facilitate the induction of sleep, and increase the duration of sleep on the advice of an appropriate secondary care specialist, in the following situations: 1) Visually impaired or blind people with disturbed sleep wake cycles. 2) Delayed sleep phase syndrome and other circadian rhythm disorders. 3) Children with neurological or behavioural disorders including: Attention deficit hyperactivity disorder (ADHD).* Chronic sleep onset insomnia.* Neurodevelopmental disabilities (e.g. involving delayed brain maturation, sensory dysfunction - especially visual and dysfunction of sleep centres).* 4) Treatment of children and young adults with chronic fatigue syndrome / myalgic encephalomyelitis who have sleep difficulties (as recommended in NICE clinical guideline no. 53).* 5) Prior to examinations such as a sleep encephalogram (EEG) in children and sedation prior to scans in paediatric oncology. 6) Patients with REM sleep behaviour disorder (RBD) - e.g. associated with degenerative conditions such as Parkinson s disease or dementia, as a second line treatment to clonazepam. 7) To improve nocturnal sleep in critically ill patients (to aid weaning from mechanical ventilation). *Note that for indications 3 and 4 in children and young people melatonin is classified as an amber drug by the NoT APC therefore subject to formal shared care guidance. This is available at: March-2013.pdf The use of melatonin for the above indications is unlicensed. It is usually used as a second or third line therapy - where sleep problems are adversely affecting quality of life in patients where other methods of management, including non pharmacological treatments, have failed to work, are not tolerated or are impracticable. North of Tyne Area Prescribing Committee Page 1 of 5
2 Dose As advised by specialist - typically: Children and Adults: Initially 2 to 3mg at night, increased if necessary after 1-2 weeks to 4-6mg at night. Usual maximum dose is 10mg at night. For circadian rhythm disorders the medication should be given at a fixed time as advised by the specialist Immediate release product the dose should be given 30 to 60 minutes before bedtime Modified release melatonin product should be given 1-2 hours before bedtime and after food Treatment should be stopped in those who fail to respond to the maximum dose. In those requiring long-term treatment, the specialist may advise attempting a reduction in dose after several months in patients who have settled into a regular sleep pattern. Monitoring Treatment with melatonin should be initiated and supervised by a specialist and if used long-term, the need for continuing therapy should be reviewed regularly. Treatment should be stopped in patients who do not continue to benefit from its use. Monitoring, particularly with regard to growth and pubertal/sexual development, is advised in children during long term administration, especially in those receiving melatonin for periods of a year or more. Cautions Drowsiness - Driving or other activities that put the patient or others at risk should be avoided if the patient is affected by drowsiness. Patients with autoimmune diseases or taking immunosuppressants. Patients with rare hereditary problems of galactose intolerance, the LAPP lactase deficiency or glucose-galactose malabsorption should not take Circadin brand melatonin. (contains lactose). Patients with hepatic impairment. Melatonin may worsen restless legs syndrome. Also see drug interactions. North of Tyne Area Prescribing Committee Page 2 of 5
3 Contra-indications Children under 1 year of age, pregnancy, breastfeeding, hypersensitivity to melatonin or any excipients. Not recommended for use in individuals with autoimmune diseases or hepatic impairment. Drug Interactions Fluvoxamine 5 and 8-methoxypsoralen Cimetidine Oestrogens Ciprofloxacin and other quinolones Alcohol Cigarette smoking Other hypnotics and CNS depressants Avoid use with melatonin as melatonin plasma concentrations are markedly increased (metabolism inhibited). Use with caution with melatonin, increased melatonin plasma concentration. Avoid reduces effectiveness of melatonin. May reduce melatonin concentrations. Melatonin may enhance the sedative properties of other drugs acting on the CNS e.g. benzodiazepines. Adverse Effects Melatonin is generally well tolerated and adverse reactions reported are at similar levels to those reported with placebo. Tiredness, headaches, dizziness, pharyngitis, back pain, asthenia and irritability have been reported following its use. Other rare side effects include restlessness, confusion, increased heart rate, itching and nausea. High doses can reduce body temperature. Discontinuation does not appear to be associated with withdrawal effects. North of Tyne Area Prescribing Committee Page 3 of 5
4 Formulations and Availability Melatonin is freely available to purchase in some countries as a nutritional supplement but in the UK access is restricted to supply by prescription. Since the launch of the licensed product, Circadin - melatonin 2mg modified release (m/r) tablets - in June 2008, the MHRA has restricted the importation of unlicensed formulations of melatonin. However, unlicensed formulations made in the UK remain readily available from UK licensed Special Order manufacturers. Preferred Product 2mg modified release tablets* (Available as the licensed product Circadin) Alternatives 1mg, 2mg*, 2.5mg*, 3mg, 5mg* and 10mg capsules or tablets 2mg and 3mg orodispersible tablets 1mg/ml oral solution* This is the preferred formulation for use where it is clinically appropriate Available as unlicensed medicines. See note 2 below. Notes 1. Only the products marked * are included in the North of Tyne Formulary 2. Guidance from the MHRA states that those supplying melatonin (as with other unlicensed medicines) must keep the following records for 5 years: The source of the product. The person to whom and the date on which the product was sold or supplied. The quantity of each sale or supply. The batch number of the product. Details of any adverse reactions to the product sold or supplied of which he is aware. These records must be made available for inspection by the licensing authority, and serious adverse drug reactions must be reported to the MHRA (via the yellow card scheme). To ensure that the Penn or Special Products formulation is supplied, prescribers will need to specify (e.g., Penn) on every prescription. Availability Melatonin 2mg modified release tablets (licensed) These are readily available to pharmacies through pharmaceutical wholesalers. North of Tyne Area Prescribing Committee Page 4 of 5
5 Melatonin Unlicensed Formulations These are available from a number of Special Order manufacturers/distributors including: Special Products Ltd +. Unit 16, Trade City, Avro Way, Brooklands Business Park, Weybridge, Surrey, KT13 0YF Tel: Fax: info@specialproducts.biz 2mg capsules 3mg capsules 1mg in 1ml oral solution Pharma Nord (UK) Ltd. Telford Court Morpeth Northumberland NE61 2DB Tel: Fax: rdixon@pharmanord.com 3mg tablets available as Bio- Melatonin* Penn Specials Manufacturing Tredegar, Gwent, NP22 3AA Tel: Fax: sales@pennpharm.com 1mg, 2mg, 2.5mg, 3mg, 5mg & 10mg capsules 2mg & 3mg orodispersible tablets The Specials Laboratory Ltd Unit 1 Regents Drive Low Prudhoe Industrial Estate Northumberland NE42 6PX Tel: Fax: orders@specialslab.co.uk The specials laboratory can supply a wide range of melatonin formulations At the present time the 3mg tablets from PharmaNord and the products from the Specials Products Ltd are available at a lower cost than products from other sources. + Melatonin products supplied by Special Products Ltd are currently less expensive than those supplied from most other sources. * For the initial supply PharmaNord requires a letter from a doctor stating that Pharma Nord Bio- Melatonin 3mg tablets is required as an unlicensed medicine, because the licensed product does not meet the clinical need of the patient for a stated reason. Once this has been received further supplies can be made against an order signed by a pharmacist. Costs NHS cost of treatment a 7 days 28 days Licensed Melatonin 2mg m.r. tablets (Circadin) 2mg at night b Unlicensed Melatonin Products Melatonin capsules c 2mg at night 2.5mg at night 5mg at night Melatonin 1mg/ml oral solution 3mg at night a) The above costs are based on prices from 3 suppliers and do not include any delivery charges, or VAT. Costs from others sources may differ. b) Licensed dose 2mg at night for up to 3 weeks. c) The contents of the capsules can be emptied and administered in a drink/soft food as an alternative to using the oral solution. North of Tyne Area Prescribing Committee Page 5 of 5
MELATONIN Insomnia and Sleep Disorders in Children
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Melatonin is a pineal hormone which
More informationRELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH
RELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationSHARED CARE AGREEMENT: MELATONIN (CHILDREN)
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate
More informationMelatonin Shared Care Agreement
For the treatment of sleep disorders in children with visual impairment or blindness, attention deficit hyperactivity disorder, autism (Unlicensed Use). Melatonin is licensed for the short term treatment
More informationAppendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children
Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Background Sleep disturbance in children with neurological or behavioural disorders is common and can be a major
More informationGreater Manchester Interface Prescribing Group Shared Care Guideline
Greater Manchester Interface Prescribing Group Shared Care Guideline Shared Care Guideline for Melatonin Circadin Author(s)/Originator(s): Dr Rob Rifkin Paediatrician RI Adele Gothard Paediatric Pharmacist
More informationPrimary efficacy Sleep measures in insomnia SLEEP IS NECESSARY FOR:1,2
Primary efficacy Sleep measures in insomnia SLEEP IS NECESSARY FOR:1,2 Insomnia Insomnia is a condition of unsatisfactory sleep, either in terms of sleep onset, sleep maintenance or early waking.3 Insomnia
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationMELATONIN Insomnia and Sleep Disorders in Children and Adolescents- Shared Care Agreement
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES Patient name: Date of Birth: NHS number: Patient Address: Referring Consultant/Paediatrician name and contact details: GP name and contact
More informationMelatonin shared care guideline. Document Title. Corporate: Clinical. Type of document. Brief summary of contents
Document Title Melatonin shared care guideline Type of document Corporate: Clinical Brief summary of contents Executive Director responsible for Policy: Directorate / Department responsible (author/owner):
More informationValdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals
Important information Do not discard! Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults Prescriber Guide Information for Healthcare Professionals Recommendations regarding:
More informationCambridgeshire Community Services NHS Trust: delivering excellence in children and young people s health services
Management of sleep problems in children with developmental difficulties Community Paediatrics Cambridgeshire Community Services NHS Trust: delivering excellence in children and young people s health services
More informationPROTOCOL DOES NOT COVER THE INITIATION OF NEW TREATMENT IN ADULT AND ELDERLY PATIENTS OVER THE AGE OF 55 YEARS.
LINCOLNSHIRE CLINICAL COMMISSIPONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST SHARED CARE GUIDELINE: Unlicensed use of Melatonin in the
More informationPackage leaflet: Information for the user. Melatonin Pharma Nord 3 mg, film-coated tablets melatonin
Package leaflet: Information for the user Melatonin Pharma Nord 3 mg, film-coated tablets Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationLondon New Drugs Group APC/DTC Briefing
London New Drugs Group APC/DTC Briefing Melatonin in paediatric sleep disorders Contents Introduction 2 Evidence base for melatonin 2 Safety and adverse-effects 5 Other pharmacological 6 treatments for
More informationSHARED CARE GUIDELINE For
SHARED CARE GUIDELINE For Melatonin for the Management of Sleep Wake in Children Implementation Date: April 2012 Review Date: March 2014 This guidance has been prepared and approved for use within Gateshead,
More informationMelatonin information
Melatonin information Audiology Services 0161 206 1568 All Rights Reserved 2017. Document for issue as handout. Unique Identifier: MED32(17). Review date: August 2019 Why are we giving this information
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give
More informationBenzodiazepines and Hypnotics
Benzodiazepines and Hypnotics Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out of date):
More informationEssential Shared Care Agreement Drugs for Dementia
E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient
More informationE096. Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability
E096 Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability Please complete the following details: Patient s name, address, date of birth,
More informationEssential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin)
Ref No: E056 Essential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin) Please complete the following details: Patient s name, address, date of birth, and either complete when the consultant
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationA Pharmacist s Guide to Intermezzo
A Pharmacist s Guide to Intermezzo Intermezzo (zolpidem tartrate) is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to
More informationBuccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.
Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment
More informationPATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:
Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Insomniger 10mg and 20mg Tablets (temazepam)
PACKAGE LEAFLET: INFORMATION FOR THE USER Insomniger 10mg and 20mg Tablets (temazepam) Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
More informationConsumer Medicine Information
Consumer Medicine Information Trade Name: ZOLPIDEM-DP Active Ingredient: Zolpidem tartrate Warning: Zolpidem may be associated with unusual and potentially dangerous behaviours whilst apparently asleep.
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationPATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE
SCHEDULING STATUS: S5 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: ZOXADON 0,5 mg: Each tablet contains 0,5 mg risperidone. ZOXADON 1 mg: Each tablet contains 1 mg risperidone. ZOXADON 2 mg: Each
More informationMedication Information for Parents and Teachers
Medication Information for Parents and Teachers General Information About Medication Melatonin Each child and adolescent is different. No one has exactly the same combination of medical and psychological
More informationP-RMS: FR/H/PSUR/0036/001
Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,
More informationShared Care Guidance. Vigabatrin
North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.
More informationLECTOPAM PRODUCT MONOGRAPH. bromazepam. 3 mg and 6 mg Tablets. Anxiolytic - Sedative. Date of Revision: September 6, 2018
PRODUCT MONOGRAPH LECTOPAM bromazepam 3 mg and 6 mg Tablets Anxiolytic - Sedative Hoffmann-La Roche Limited 7070 Mississauga Road Mississauga, Ontario L5N 5M8 Date of Revision: September 6, 2018 www.rochecanada.com
More informationMMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA
MMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA Page 1 of 11 Table of Contents Why we need this Guideline... 3 What the Policy is trying to do... 3 Which stakeholders have been
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationEU Core Safety Profile
EU Core Safety Profile Active Substance: Triazolam Brand Names: HALCION, SOMESE Pharmaceutical form(s)/strength: Tablets RMS: Finland Date: 9 th Dec 2013 Supersedes: 24 th May 2010 4.3. Contraindications
More informationPATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS Version No: Draft 2 Please note this PGD has been approved by SWYFT Drugs and Therapeutic Committee this is an
More informationJINARC (tolvaptan) Patient/carer education brochure
JINARC (tolvaptan) Patient/carer education brochure This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationPeterborough Nalmefene Pathway Responsibilities for Specialist Services & GP
Peterborough Nalmefene Pathway Responsibilities for Specialist Services & GP INTRODUCTION/BACKGROUND In November 2014 NICE (National Institute of Clinical Excellence) published the Technology Appraisal
More informationGuidance for use of MELATONIN for children with severe sleep disorders
Guidance for use of MELATONIN for children with severe sleep disorders Document Details Title Guidance for use of MELATONIN for children with severe sleep disorders Trust Ref No 1855-33709 Local Ref (optional)
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:
Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated
More informationPACKAGE LEAFLET. Page 1 of 8
PACKAGE LEAFLET Page 1 of 8 Package leaflet: Information for the patient Temazepam 10mg and 20mg tablets (Temazepam) Read all of this leaflet carefully before you start taking this medicine because it
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationShared Care Agreement for Donepezil, Galantamine, Rivastigmine and Memantine
Clinical SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: Date Treatment Started: Name of drug: (Add Date) One copy of information leaflet given to
More informationGuidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception
Guidance for Pharmacists on the Safe Supply of Non-Prescription Levonorgestrel 1500mcg for Emergency Hormonal Contraception Pharmaceutical Society of Ireland Version 4 December 2016 Updates made following
More informationData Sheet. Chemical name: N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide. Melatonin is a slightly off-white, odourless crystalline powder.
Data Sheet CIRCADIN Prolonged Release Tablets Melatonin 2 mg Name of the Medicine Melatonin Chemical name: N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide. Melatonin is a slightly off-white, odourless crystalline
More informationPATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE (Approved May 2014 - Review Date May 2016) GENERAL POLICY PATIENT GROUP DIRECTION
More informationObjectives. Types of Sleep Problems in Developmental Disorders
Objectives Sleep Problems in the Child with Neurodevelopmental Disorders AACPDM September 11, 2014 BRK-3 Golda Milo-Manson MD, MHSc, FRCP(C) Holland Bloorview Kids Rehabilitation Hospital Toronto, Canada
More informationShared Care Guideline Stiripentol use for SCN1A related and Severe Myoclonic Epilepsies in Infancy
Shared Care Guideline Stiripentol use for SCN1A related and Severe Myoclonic Epilepsies in Infancy Executive Summary 1. Indication Stiripentol is indicated for use in conjunction with clobazam and valproate
More informationEffective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine
Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This
More informationPatient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationShared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults
Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no:
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationHydroxychloroquine (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: Hydroxychloroquine (Adults) Indication: Rheumatoid arthritis and inflammatory osteoarthritis, discoid and systemic lupus erythematosus,
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic
More informationInsomnia. Learning Objectives. Disclosure 6/7/11. Research funding: NIH, Respironics, Embla Consulting: Elsevier
Insomnia Teofilo Lee-Chiong MD Professor of Medicine National Jewish Health University of Colorado Denver School of Medicine Learning Objectives Learn about the causes of transient and chronic Learn how
More informationConduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)
E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:
More informationDownstream product market research of Melatonin
Downstream product market research of Melatonin Product name and physical & chemical properties Product Usage Product principle / mechanism Melatonin (N-acetyl-5-methoxytryptamine), also known as pinealin,
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine
More informationClozapine Clinic Treatment Centre, St Georges Park
Clozapine Clinic Treatment Centre, St Georges Park Patient Information Leaflet Shining a light on the future This leaflet is relevant to the following clinic: St Georges Park Hospital Morpeth Northumberland
More informationInsomnia Management Guideline
Insomnia Management Guideline Guideline Development This document is an update of existing guidance and has been developed by Barnsley CCG Medicines Management Team in consultation with colleagues from
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationFactsheet. Buccolam (midazolam) 10mg in 2mL oromucosal solution. Management of seizures in adult patients
North Central London Joint Formulary Committee Factsheet Buccolam (midazolam) 10 mg in 2 ml oromucosal solution Management of seizures in adult patients Start date: May 2017 Review date: May 2020 Document
More informationMetformin MR to low cost branded generic (Sukkarto SR) Switch Protocol
Metformin MR to low cost branded generic (Sukkarto SR) Switch Protocol Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the NY&AWC MM team
More informationA new model for prescribing varenicline
Pharmacist Independent Prescribers in partnership with A new model for prescribing varenicline Dear Stop Smoking Advisor You will be aware of the stop smoking drug varenicline that goes under the brand
More informationShared Care Guideline for Olanzapine (Zyprexa )
Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationLocal Omalizumab Treatment Protocol (For children 6 to <12 years of age)
Local Omalizumab Treatment Protocol (For children 6 to
More informationNew data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome
New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationPRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)
PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of
More informationPackage leaflet: Information for the user. Zolpidem Vitabalans 10 mg film-coated tablets zolpidem tartrate
Package leaflet: Information for the user Zolpidem Vitabalans 10 mg film-coated tablets zolpidem tartrate Read all of this leaflet carefully before you start using this medicine because it contains important
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationDrug Review Rozerem (ramelteon)
Drug Review Rozerem (ramelteon) Introduction 1 Ramelteon is a melatonin receptor agonist with affinity for MT 1 and MT 2 and selectivity over the MT 3 receptor. The activity at the MT 1 and MT 2 receptors
More informationPATIENT INFORMATION LEAFLET TEXAMER
SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: film-coated tablets Read all of this leaflet carefully because it contains important information for you. is available without a doctor s prescription,
More informationPrescribing Framework for Naltrexone in Alcohol Relapse Prevention
Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient
More informationPATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:
SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationDonepezil, Rivastigmine and Galantamine (TLS Amber with shared care) Donepezil (TLS green Wilts)
Donepezil, Rivastigmine and Galantamine (TLS Amber with shared care) Donepezil (TLS green Wilts) Shared Care Guidelines: For the treatment of Alzheimer s disease It is intended to apply to patients who
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More information